E-mail

E-mail a Wiley Online Library Link

Martee L. Hensley, Sara Kravetz, Xiaoyu Jia, Alexia Iasonos, William Tew, Lauren Pereira, Paul Sabbatini, Christin Whalen, Carol A. Aghajanian, Corinne Zarwan and Suzanne Berlin Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer Cancer 118

Article first published online: 20 SEP 2011 | DOI: 10.1002/cncr.26569

Eribulin produces objective responses in 5.5% of women with platinum-resistant, recurrent ovarian cancer and in 19% of women with platinum-sensitive disease. The median progression-free survival is 1.8 months in the platinum-resistant group and 4.1 months in the platinum-sensitive group.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

Choose captcha format: Image or Audio. Click here if you need help.

SEARCH